W R Greco - JoVE Visualize

Showing results (1-10 of 31) with videos related to

Pageof 4

Sort By:

Cancer Research|April 1, 1986

Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assaysS M Camiolo, W R Greco

Cancer Research|September 1, 1990

Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosineW R Greco, H S Park, Y M Rustum

Cancer Research|April 15, 1992

Quantitation of folic acid enhancement of antifolate synergismY Gaumont, R L Kisliuk, J C Parsons, et al.

Journal of Pharmacokinetics and Biopharmaceutics|September 15, 1999

Implications for clinical pharmacodynamic studies of the statistical characterization of an in vitro antiproliferation assayL M Levasseur, H Faessel, H K Slocum, et al.

Academic Radiology|May 10, 2001

Brain MR imaging in the evaluation of chronic headache in patients without other neurologic symptomsH Z Wang, T M Simonson, W R Greco, et al.

Annals of the New York Academy of Sciences|February 24, 2001

In vitro antitumor activity of 9-nitro-camptothecin as a single agent and in combination with other antitumor drugsR J Bernacki, P Pera, P Gambacorta, et al.

Cancer Chemotherapy and Pharmacology|January 1, 1997

Combined action of paclitaxel and cisplatin against wildtype and resistant human ovarian carcinoma cellsL M Levasseur, W R Greco, Y M Rustum, et al.

In Vitro Cellular & Developmental Biology. Animal|September 4, 1999

Parabolic growth patterns in 96-well plate cell growth experimentsH M Faessel, L M Levasseur, H K Slocum, et al.

Cancer Research|December 29, 1998

Modeling of the time-dependency of in vitro drug cytotoxicity and resistanceL M Levasseur, H K Slocum, Y M Rustum, et al.

Biochemical Pharmacology|February 10, 1999

Folic acid-enhanced synergy for the combination of trimetrexate plus the glycinamide ribonucleotide formyltransferase inhibitor 4-[2-(2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4,6][1,4]thiazin -6-yl)-(S)-ethyl]-2,5-thienoylamino-L-glutamic acid (AG2034): comparison across sensitive and resistant human tumor cell linesH M Faessel, H K Slocum, Y M Rustum, et al.

Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:

Pageof 4

Cancer Research|April 1, 1986

Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assaysS M Camiolo, W R Greco

Cancer Research|September 1, 1990

Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosineW R Greco, H S Park, Y M Rustum

Cancer Research|April 15, 1992

Quantitation of folic acid enhancement of antifolate synergismY Gaumont, R L Kisliuk, J C Parsons, et al.

Journal of Pharmacokinetics and Biopharmaceutics|September 15, 1999

Implications for clinical pharmacodynamic studies of the statistical characterization of an in vitro antiproliferation assayL M Levasseur, H Faessel, H K Slocum, et al.

Academic Radiology|May 10, 2001

Brain MR imaging in the evaluation of chronic headache in patients without other neurologic symptomsH Z Wang, T M Simonson, W R Greco, et al.

Annals of the New York Academy of Sciences|February 24, 2001

In vitro antitumor activity of 9-nitro-camptothecin as a single agent and in combination with other antitumor drugsR J Bernacki, P Pera, P Gambacorta, et al.

Cancer Chemotherapy and Pharmacology|January 1, 1997

Combined action of paclitaxel and cisplatin against wildtype and resistant human ovarian carcinoma cellsL M Levasseur, W R Greco, Y M Rustum, et al.

In Vitro Cellular & Developmental Biology. Animal|September 4, 1999

Parabolic growth patterns in 96-well plate cell growth experimentsH M Faessel, L M Levasseur, H K Slocum, et al.

Cancer Research|December 29, 1998

Modeling of the time-dependency of in vitro drug cytotoxicity and resistanceL M Levasseur, H K Slocum, Y M Rustum, et al.

Biochemical Pharmacology|February 10, 1999

Folic acid-enhanced synergy for the combination of trimetrexate plus the glycinamide ribonucleotide formyltransferase inhibitor 4-[2-(2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4,6][1,4]thiazin -6-yl)-(S)-ethyl]-2,5-thienoylamino-L-glutamic acid (AG2034): comparison across sensitive and resistant human tumor cell linesH M Faessel, H K Slocum, Y M Rustum, et al.

Pageof 4